Managing obesity like any other chronic condition: Long-term therapy may reduce comorbidity as well

Postgraduate Medicine

Volumn 108, Issue 1, 2000, Pages 75-82

  Agrawal, Mamatha ^a   Worzniak, Michael ^a   Diamond, Larry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

'CONTROL'; AMFEPRAMONE; CAFFEINE; CHLORPHENOXAMINE; EPHEDRINE; FLUOXETINE; MAZINDOL; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; CHRONIC DISEASE; COMORBIDITY; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; OBESITY; RISK BENEFIT ANALYSIS; WEIGHT REDUCTION;

EID: 0033928348     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2000.07.1158     Document Type: Article

References (22)

1. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276(23):1907-15
2. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes 1998;106 (Suppl 2):29-34
3. Lean MEJ, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990;7(3): 228-33
4. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69(6): 1108-16
5. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998;21(8):1288-94
6. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281(3): 235-42
7. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352(9123):167-72
8. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106(2):179-84
9. Abenhaim L, Moride Y, Brenot F, et al, for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335(9):609-16
10. Thomas SH, Butt AY, Corris PA. Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Bt Heart J 1995;74(6):660-3
11. Simonneau G, Fartoukh M, Sitbon O, et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998;114(3 Suppl):195-9S
12. Connolly HM, Crary JL, McGoon MD. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337(9):581-8
13. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994;60(5):647-57
14. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51(5): 581-5, 642-6
15. Munro JF, Maccuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968;1:352-4
16. Van Gaal LF, Wauters MA, De Leeuw IH. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contributions to obesity treatment. Exp Clin Endocrinol Diabetes 1998; 106(Suppl 2):35-40
17. Lean ME. Sibutramine - a review of clinical efficacy. Int J Obes Relat Metab Disord 1997;(21 Suppl 1):30-6S
18. Levine LR, Enas GG, Thompson WL, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obes 1989;13(5):635-45
19. Beckwith C. Ma huang and ephedrine in dietary supplements. The Pharmacist's Letter Mar 1999;16
20. Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998; 280(18):1596-600
21. Badmaev V, Majeed M, Conte AA. Garcinia combogia for weight loss. (Letter) JAMA 1999;282(3):233-4
22. Schaller JL. Garcinia cambogia for weight loss. (Letter) JAMA 1999;282(3): 234